Close Menu

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Wednesday that Laboratory Corporation of America has joined its "Day-One" lab readiness program designed to expedite patient access to Qiagen companion diagnostic products following regulatory approval of the tests and associated drugs.

Qiagen's Day-One program is intended to enable molecular diagnostic labs to begin preparing for commercial launch of new drugs and in vitro diagnostic tests being developed by Qiagen and its partners once US Food and Drug Administration approval is obtained.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.